Climb Bio, Inc. Common Stock CLYM
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T14:52:22.118Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:52:15.068355749Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T14:52:21.685506+00:00
Climb Bio, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 10.33 | 147.7% | 18.2% | |||
| 25Δ | 10.60 | 170.0% | 17.8% | |||
| 30Δ | 10.87 | 192.4% | 17.4% | |||
| 35Δ | 14.90 | 229.7% | 30.5% | 11.20 | 195.2% | 15.9% |
| 40Δ | 11.60 | 179.1% | 13.3% | |||
| 45Δ | 12.47 | 95.2% | 7.9% | 12.00 | 162.9% | 10.7% |
| 50Δ | 12.27 | 91.8% | 7.0% | 12.40 | 146.7% | 8.2% |
| 55Δ | 12.07 | 88.3% | 6.1% | 12.86 | 147.8% | 6.9% |
| 60Δ | 11.88 | 84.9% | 5.2% | 13.33 | 154.7% | 6.0% |
| 65Δ | 11.68 | 81.4% | 4.3% | 13.81 | 161.6% | 5.1% |
| 70Δ | 11.48 | 78.0% | 3.4% | |||
| 75Δ | 11.28 | 74.5% | 2.5% | |||
| 80Δ | 11.08 | 71.1% | 1.6% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.33
- IV
- 147.7%
- B/E move
- 18.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.60
- IV
- 170.0%
- B/E move
- 17.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.87
- IV
- 192.4%
- B/E move
- 17.4%
35Δ
- Pseudo strike
- 14.90
- IV
- 229.7%
- B/E move
- 30.5%
- Pseudo strike
- 11.20
- IV
- 195.2%
- B/E move
- 15.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.60
- IV
- 179.1%
- B/E move
- 13.3%
45Δ
- Pseudo strike
- 12.47
- IV
- 95.2%
- B/E move
- 7.9%
- Pseudo strike
- 12.00
- IV
- 162.9%
- B/E move
- 10.7%
50Δ
- Pseudo strike
- 12.27
- IV
- 91.8%
- B/E move
- 7.0%
- Pseudo strike
- 12.40
- IV
- 146.7%
- B/E move
- 8.2%
55Δ
- Pseudo strike
- 12.07
- IV
- 88.3%
- B/E move
- 6.1%
- Pseudo strike
- 12.86
- IV
- 147.8%
- B/E move
- 6.9%
60Δ
- Pseudo strike
- 11.88
- IV
- 84.9%
- B/E move
- 5.2%
- Pseudo strike
- 13.33
- IV
- 154.7%
- B/E move
- 6.0%
65Δ
- Pseudo strike
- 11.68
- IV
- 81.4%
- B/E move
- 4.3%
- Pseudo strike
- 13.81
- IV
- 161.6%
- B/E move
- 5.1%
70Δ
- Pseudo strike
- 11.48
- IV
- 78.0%
- B/E move
- 3.4%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 11.28
- IV
- 74.5%
- B/E move
- 2.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 11.08
- IV
- 71.1%
- B/E move
- 1.6%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 132.47% | |
| 132.54% | |
| 130.66% | |
| 136.72% | |
| 133.08% | |
| 127.24% | |
| 129.45% | |
| 156.63% | |
| 114.73% | |
| 121.75% |
Biotechnology
CMPX
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The…
More →CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe…
More →COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge,…
More →CORT
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company…
More →COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is…
More →CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid…
More →